Sigilon Therapeutics to Present at the GTCbio 15th Stem Cell Summit
CAMBRIDGE, Mass., April 6, 2018 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the GTCbio 15th Stem Cell Summit being held April 12-13, 2018, in Boston. Presentation details are as follows:
GTCbio 15th Stem Cell Summit
Presenter: Devyn Smith, Ph.D., Chief Strategy Officer and Head of Operations Date: Thursday, April 12, 2018 Time: 2.35 p.m. EDT Location: Hyatt Regency Boston Hotel
About Sigilon Therapeutics
Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics' Afibromer™ technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.